Merck partners with Habitat for Humanity in asthma awareness effort

Share this article:
Merck partners with Habitat for Humanity in asthma awareness effort
Merck partners with Habitat for Humanity in asthma awareness effort
Merck is launching Build Smart, Breathe Easier, an asthma awareness campaign starring celebrity carpenter Carter Oosterhouse, who will build four homes with asthma-healthy features.

Oosterhouse, a fixture on HGTV, will build houses with low-income families that suffer from asthma in Atlanta, Detroit, LA and Philadelphia as part of the campaign, for which Merck is partnering with Habitat for Humanity and the Asthma and Allergy Foundation of America (AAFA). The campaign will emphasize the use of easy-to-clean, irritant-free materials, such as non-toxic paint and hard-surface floors, as a means of limiting asthma flare-ups, and will raise awareness of household asthma triggers such as dust mites, mold, pet dander and strong fumes and ways to control them.

Merck and AAFA employees will volunteer their labor on the homes, working alongside Oosterhouse and four families selected by Habitat for Humanity on homes built according to the principles of AAFA's Asthma and Allergy Friendly Certification Program.  

"Our goal is to educate about how to take steps to try to reduce triggers in the home," said Oosterhouse on the campaign's Facebook page, "and to encourage people with asthma to speak with their doctor about the appropriate treatment approach for their individual needs."

The campaign's Facebook page, though bereft of branding, does link to Merck-branded “asthma tracking tool (MerckEngage),” “self-management action plan” and “therapy assessment questionnaire.”

Merck's respiratory portfolio includes Asmanex, Dulera, Foradil, Proventil and Singulair for asthma as well as Clarinex and Nasonex for allergies.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...